加载中
NASDAQHealthcareMedical - Devices
最新数据
US$18.40
+US$0.50 · +2.79%
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
前收盘价
US$18.40
+US$0.50 · +2.79%
盘中时间采用ET。市场数据可能有所延迟。
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
日内区间
当前US$18.40
52周区间
当前US$18.40
盘中时间采用ET。市场数据可能有所延迟。
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
日内区间
当前US$18.40
52周区间
当前US$18.40
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 3.08亿 USD | 2.24亿 USD | 1.36亿 USD | 7501.4万 USD | 3447.3万 USD |
| 销货成本 | 1.12亿 USD | 8739.9万 USD | 6514.2万 USD | 3792.9万 USD | 1860.8万 USD |
| 毛利 | 1.96亿 USD | 1.37亿 USD | 7104.9万 USD | 3708.5万 USD | 1586.5万 USD |
| 研究与开发 | 7127.7万 USD | 6229.8万 USD | 4844.6万 USD | 2898.1万 USD | 1899.3万 USD |
| 销售、一般及管理费用 | 2.29亿 USD | 1.71亿 USD | 1.32亿 USD | 8882.8万 USD | 5103.6万 USD |
| 营业费用 | 3亿 USD | 2.34亿 USD | 1.8亿 USD | 1.18亿 USD | 7002.9万 USD |
| 利息收入 | 1221.9万 USD | 1089.5万 USD | 755.1万 USD | 249.7万 USD | 7.6万 USD |
| 利息支出 | 358.6万 USD | 418.4万 USD | 399.5万 USD | 518.3万 USD | 581万 USD |
| 折旧和摊销 | 639万 USD | 523.4万 USD | 380.7万 USD | 284.1万 USD | 332.4万 USD |
| 营业利润 | −1.04亿 USD | −9661.4万 USD | −1.09亿 USD | −8072.4万 USD | −5416.4万 USD |
| 净利润 | −9557.2万 USD | −9141.3万 USD | −1.06亿 USD | −8715.4万 USD | −5985.3万 USD |
公司数据更新于 2026年10月11日。
第三方分析师预期可能变化，并非 GoAI 建议。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
